Clinical Trials Browser

Completed × Leukemia, Myeloid, Chronic-Phase × BID protein, human × Clear all

NCT01856283 2021-01-13

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase